BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, June 11, 2026
Home » Blogs » BioWorld MedTech Perspectives » Med-tech from the battlefield

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

Medical technology

Med-tech from the battlefield

Aug. 12, 2013
By Amanda Pedersen

wounded-warriorsA decade ago it would have been hard to imagine a bioabsorbable tissue-lined stent graft capable of treating blood vessels that have been ripped apart by a bomb, or a spray-on solution that would promote the regrowth of your own skin after a traumatic injury or burn, or even a portable machine that could treat deadly infections like sepsis in much the same way that dialysis machines treat kidney failure. But today these innovations and many more are being developed to treat wounded warriors and will someday be used not just on the battlefield but in civilian hospitals as well. This week Medical Device Daily will be reporting on the various ways that combat needs have influenced R&D for medical technology in a three-part series. Of course this is not a new phenomenon but something that has occurred throughout history, as far back as World War I and beyond. Probably for as long as battles have existed, war wounds have played a role in advancing medicine on the homefront. But what has changed is the types of injuries that combat medics and surgeons have had to deal with during these two most recent conflicts overseas, primarily because the military now has such advanced, high-tech body armor and armored vehicles, that soldiers are now surviving blasts that otherwise might have killed them. That’s why the majority of injuries these wounded warriors suffer from have been quite traumatic and life-altering, like amputations, paralysis and severe burns. As a military spouse I’m sensitive to the sacrifice that these wounded warriors have made and I am grateful that organizations like the Armed Forces Institute of Regenerative Medicine (AFIRM) at Fort Detrick, Maryland have been able to fund so many R&D projects to advance combat treatment. My fear is that as the U.S. pulls out of Iraq and Afghanistan the government will also stop funding this type of research. During an interview with Maj. Louis Alvarez of the AFIRM, he expressed similar concerns. “We want to maintain awareness and visibility of these injuries that will be lifelong and traumatic,” he said. “... We should maintain as much momentum as possible,” on these fronts.

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 10, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 9, 2026
  • 3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

    Skape Bio unlocks GPCR targets with de novo-designed miniproteins

    BioWorld
    Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
  • Wuxi Apptec signage

    Wuxi Apptec insists it’s ‘not a Chinese military company’

    BioWorld
    Wuxi Apptec isn’t going down without a fight after the U.S. Department of Defense added it to the Section 1260H list June 8 as a designated “Chinese military...
  • Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors

    BioWorld Science
    Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing